Aczone (Dapsone) Patent Expiration, LOE Window & CMS Spending

Aczone (Dapsone) by Almirall: FDA Orange Book LOE 2033-11-18, 13 AB generics, $78K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAlmirall
FDA Application & PathwayN021794 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2033-11-18
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors13
2024 CMS Total Public Spend$78K
2024 Medicare Part D Spend$78K
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel